AVI BioPharma has reported a revenue of $2.9m for the second quarter of 2009, a decrease when compared to $5.0m in the prior-year period.
The company has reported a revenue of $6.1m for the first half of 2009, a decrease when compared to $10.6m for the first half of 2008.
The company has reported a net loss of $19.7m, or $0.23 per share for the second quarter of 2009, compared with a net loss of $1.8m, or $0.02 per share for the second quarter of 2008.
The company has reported a net loss of $20.6m, or $0.25 per share for the six months ended June 30, 2009, compared with a net loss of $16.8m, or $0.25 per share for the comparable period in 2008.
Leslie Hudson, president and CEO of AVI BioPharma, said: The first half of 2009 has been a period of sustained progress on several fronts for AVI, as we have secured a number of important new contracts and collaborations to support the advance of our promising development programs, including those for Duchenne muscular dystrophy. We have established our claim as an innovator in the development of exon skipping technology, as well as, the development of antiviral therapeutics targeting H1N1 and potential biological threats such as Ebola, Marburg and JunÃn viruses.